The OlympiAD trial (NCT02000622) is a phase 3 randomized study to examine the efficacy of olaparib, a PARP1 inhibitor, for patients with metastatic, germline BRCA mutated, HER2-negative breast cancer, and who had received no more than two previous lines of chemotherapy or treatments of physician’s choice [190]. This evidence concerns the gene PARP1 and breast cancer.